Allergan’s Profit Rises 45 Percent on Stronger Botox Sales

Allergan’s first-quarter earnings rose 45 percent as the maker of Botox and medical devices reported double-digit sales growth at its specialty pharmaceuticals business. The company projected second-quarter results below analysts’ expectations, with earnings of $1.04 to $1.06 a share on revenue of $1.45 billion to $1.5 billion.
The Wall Street Journal